B-cell Non-Hodgkin Lymphoma – Pipeline Review, 2019

B-Cell Non-Hodgkin lymphoma is a rare type of cancer which develops in the lymph nodes. These lymphomas usually develop in adult and immunocompromised populations. There are various subtypes of B-cell Non-Hodgkin Lymphoma which includes Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma Mantle Cell Lymphoma and Primary Central Nervous System Lymphoma. Among them, Diffuse Large B-Cell Lymphoma is the most commonly diagnosed B-cell non-Hodgkin lymphoma which is generally aggressive with rapidly growing tumors in the spleen, bone marrow, and other organs. According to the Lymphoma Research Foundation (LRF), it is estimated that around 18,000 people are diagnosed with diffuse large B-cell lymphoma globally.

Swelling of lymph nodes in neck & armpit, persistent fatigue, chest pain, fever, and unexplained weight loss are some of the symptoms associated with B-cell non-Hodgkin lymphoma. Current treatment of B-cell non-Hodgkin lymphoma includes chemotherapy, cell-based therapies, and sometimes targeted therapies are used as treatment options for the treatment of B-cell non-Hodgkin lymphoma at the early stage.

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for B-cell non-Hodgkin lymphoma. For instance; JNJ-67856633, which is being studied by Janssen Global Services, LLC, is currently in phase-1 clinical trials for the study of JNJ-67856633 in participants with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).

At present around 89% of the pipeline candidates for B-cell Non-Hodgkin's Lymphoma are in the phase-1 and phase-2 stage. More than half of the studies are sponsored by industry.

Report Description

The report on ‘B-cell Non-Hodgkin Lymphoma – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Acromegaly. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for B-cell Non-Hodgkin Lymphoma.

The report on ‘B-cell Non-Hodgkin Lymphoma – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Acromegaly
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Acromegaly
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary